26093
document
Evaluation of prostaglandin E1 for prevention of respiratory failure in high risk trauma patients : a prospective clinical trial and correlation with plasma suppressive factors for neutrophil activation . A group of 48 critically injured patients were entered into a prospective , double-blind , placebo-controlled trial to evaluate the efficacy of early infusion of PGE1 for reducing the incidence of severe respiratory failure and mortality . Secondary assessments examined the effects of the PGE1 infusion on plasma mediated suppression of PMN superoxide production and loss of PMN granule enzyme content . The incidence of severe respiratory failure was lower in the PGE1 group -- 13 % versus 32 % , but this did not reach significance . The overall morality was equivalent between the two groups -- 26 % ( PGE1 ) versus 28 % ( placebo ) . The suppressive activity of the patient plasma was assayed by measurement of normal PMN superoxide production relative to normal control plasma ( ratio P : C ) . The baseline ratio P : C was 62 +/- 5 % in the PGE1 group versus 60 +/- 5 % in the placebo group . The day 1 plasma samples showed significant reversal of plasma suppressive activity in the PGE1 group -- ratio P : C 88 +/- 5 % versus 67 +/- 5 % in the placebo group ( P less than 0.02 ) . In patients who received the full 7 days of infusion , the plasma suppressive activity remained significantly diminished in the PGE1 group -- ratio P : C 77 +/- 4 % versus 61 +/- 5 % ( P less than 0.04 ) . The baseline lysozyme content of patient PMN 's relative to that of normal control PMNs ( ratio P : C ) was 119 +/- 14 % in the PGE1 group . A significant loss of lysozyme content was observed in the PGE1 group on day 1 of the infusion -- ratio P : C 79 +/- 8 % ( P less than 0.03 ) , and was associated with a reduction in the plasma suppressive activity . ( ABSTRACT TRUNCATED AT 250 WORDS )
26094
Intervention_Pharmacological
prostaglandin E1
26095
Intervention_Control
placebo-controlled
26096
Intervention_Pharmacological
early infusion of PGE1
26097
Intervention_Pharmacological
PGE1
26098
Intervention_Control
placebo
26099
Outcome_Mortality
incidence of severe respiratory failure and mortality
26100
Outcome_Physical
severe respiratory failure
26101
Outcome_Physical
plasma suppressive activity
26102
Outcome_Physical
plasma suppressive activity
26103
Participant_Condition
high risk trauma
26104
Participant_Sample-size
48
26105
Participant_Condition
critically injured